Trials / Completed
CompletedNCT00433888
Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)
Clinical Study of Switching From rHuEPO to R744 and Maintenance Treatment With R744 in Renal Anemia Patients on Hemodialysis (Phase Ⅲ Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 179 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of intravenous R744 in renal anemia patients on hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R744 | 100μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks |
| DRUG | R744 | 150μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-07-01
- Completion
- 2008-10-01
- First posted
- 2007-02-12
- Last updated
- 2009-02-02
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00433888. Inclusion in this directory is not an endorsement.